The clinical efficacy data for PARP inhibitors in cancer patients with deleterious BRCA gene mutations are consistent with the in vitro cytotoxicity levels of the PARP inhibitors, nicely correlating the clinical activity with the ability to trap PARP [204]. This evidence concerns the gene PARP1 and cancer.